Baltimore, Maryland 21201

  • AML


The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).

Study summary:

Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the Maximum Tolerated Dose and Schedule (MTDS) Expansion Cohort Segment (ongoing). Having characterized safety and determined the maximum tolerated dose and schedule, the primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR or CRh. Starting with Cycle 2, patients who are benefiting from flotetuzumab may receive up to a maximum of 8 cycles of treatment.


Inclusion Criteria: - Confirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification - Patients with AML must meet one of the following criteria, a or b: a. Primary Induction Failure (PIF) AML, defined as disease refractory to one of the following, i or ii: i. An intensive induction attempt, per institution. Induction attempts include high-dose and/or standard-dose cytarabine ± an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth factor or targeted therapy containing regimens. Examples include but are not limited to: 1. One cycle of high dose cytarabine (HiDAC) containing regimen 2. One cycle of liposomal cytarabine and daunorubicin 3. Two cycles of standard dose cytarabine containing regimen ii. For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens, 1 or 2: 1. ≥ 2 but ≤ 4 cycles of Bcl-2 inhibitors in combination with azacitidine, decitabine, or low dose cytarabine 2. ≥ 2 but ≤ 4 cycles of gemtuzumab ozogamicin monotherapy b. Early relapse (ER) AML, defined as AML in first relapse with initial CR1 duration < 6 months 3. Limit of 3 prior lines of therapy: up to 2 induction (induction, re-induction) or 1 induction plus/minus 1 consolidation attempt, followed by a maximum of 1 salvage/re-induction attempt. - Eastern Cooperative Oncology Group (ECOG) performance status ≤2 - Life expectancy of at least 4 weeks - Peripheral blast count </= 20,000/mm3 at the time of first dose - Acceptable laboratory parameters and adequate organ reserve Exclusion Criteria: - History of allogeneic stem cell transplantation - Prior treatment with an anti-CD123-directed agent - Need for concurrent other cytoreductive chemotherapy - Any active untreated autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and with stable supplementation) - Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is allowed. - Antitumor therapy or investigational agent within 14 days or 5 half-lives of Cycle 1 Day 1. - Requirement, at the time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, otic preparations, nasal spray or ophthalmic solution - Use of immunosuppressant medications in the 2 weeks of Cycle 1 Day 1 - Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating factor in the 2 weeks of Cycle 1 Day 1 - Known central nervous system (CNS) leukemia - Active uncontrolled infection (including, but not limited to viral, bacterial, fungal, or mycobacterial infection), - Known human immunodeficiency virus infection, unless all of the following criteria are met: i. CD4+ count ≥ 350 cells/μL, ii. undetectable viral load, and iii. receiving highly active antiretroviral therapy. - Known, active, history of or current acute or chronic hepatitis B or C virus (HBV) infection (as evidenced by detectable HBV surface antigen and HBV DNA ≥ 500 IU/mL), - History of hepatitis C virus (HCV) infection, unless the infection has been treated and cured, - Active SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing for ongoing infection should follow local clinical practice guidelines/standards. Participants with a positive test result for ongoing SARS-CoV-2 infection, known asymptomatic infection, or suspected infection are excluded unless or until asymptomatic and with subsequent negative SARS-CoV-2 laboratory test.



Primary Contact:

Principal Investigator
John DiPersio, MD, PhD
Washington University School of Medicine

Kathy Tran

Backup Contact:


Location Contact:

Baltimore, Maryland 21201
United States

Veronica Kflu
Phone: 410-328-9416

Site Status: Recruiting

Data Source:

Date Processed: September 28, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.